HOME >> BIOLOGY >> NEWS
LA BioMed Medical/Research Briefs, July/August 2004

  • LA BioMed Supports Stem Cell Initiative
  • Ethnic Breast Cancer?
  • A Periodic Table For Biology

    La BioMed Supports Stem Cell Initiative

    In coalition with major health and business groups throughout California, LA BioMed has indicated its support for the California Stem Cell Bond Issue Initiative that recently qualified for November's ballot. The initiative will allocate money from a $3 billion bond to fund promising, California-based stem cell research.

    The initiative will distribute an average of $295 million per year over a 10-year period to fund stem cell research at California's universities and other advanced medical research facilities. It will fund all aspects of stem cell therapy development from basic research through clinical trials to the actual delivery of therapies to patients.

    Kenneth P. Trevett, President and CEO of LA BioMed, recently issued the following statement about the initiative:

    The stem cell initiative is a necessary step in the pursuit of scientific research because federal funding for stem cell research has been limited. Unquestionably, stem cell therapy is potentially the most important medical advance since the discovery of antibiotics. This critically important statewide initiative closes the federal funding gap and sets a new state model for advancing scientific research. From an economic standpoint, California will benefit from patents and royalties that result from the research. Construction of research facilities and new research jobs will generate millions of dollars in new tax revenues for California. More importantly, if stem cell research results in a single cure that reduces healthcare costs by just one percent, it would pay for itself several times over during the following decade and save lives along the way.

    Mr. Trevett is available to speak the merits of the stem cell initiative. To contact him, telephone or e-mail the Communicatio
    '"/>



  • Contact: David Feuerherd
    df@issuesmanagement.com
    310-215-0234
    Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
    30-Jul-2004


    Page: 1 2 3

    Related biology news :

    1. BioMed Central to consult funders and librarians over Open Access payment model
    2. BioMed Central explodes Open Access myths
    3. The Scientist and BioMed Central come together to publish high-impact magazine
    4. BioMed Central is pleased to announce the publication of Sydney Brenners autobiography
    5. BioMed Central to deposit e-journals with the British Library
    6. BioMed Central to consider charging authors for paper submissions
    7. Get Research on the move with BioMed Central
    8. BioMed Central to launch at microbiology meeting
    9. BioMed Central to free scientists and clinical researchers from copyright restrictions

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: BioMed Medical Research Briefs July August

    (Date:10/16/2014)... 2014) – Post-menopausal women experienced improvements in vaginal ... or genital bleeding, after 12 weeks of daily ... soy germ-based nutritional supplement previously shown to help ... peer-reviewed pilot study reported in a poster at ... meeting. , "These data documented improved vaginal ...
    (Date:10/15/2014)... non-traditional biophysics textbook and it describes how life functions ... discovery into biological systems and provides an understanding of ... about how our genes make proteins that control the ... in an organism. It quantifies the principles of life ... found on both large and small scales. The book ...
    (Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
    Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
    (Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
    (Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
    (Date:10/22/2014)... 2014 Physicians Choice Laboratory Services ... menu, which enables healthcare providers to individualize therapeutic ... evidence-based results, healthcare providers are better able to ... while minimizing risks for adverse drug reactions and ... the FDA [1] more than 2.2 million adverse ...
    (Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
    Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
    Cached News: